CDC Clinical Practice Guideline for Prescribing Opioids for Pain - United States, 2022
MMWR Recomm Rep. 2022 Nov 4;71(3):1-95. doi: 10.15585/mmwr.rr7103a1.ABSTRACTThis guideline provides recommendations for clinicians providing pain care, including those prescribing opioids, for outpatients aged ≥18 years. It updates the CDC Guideline for Prescribing Opioids for Chronic Pain - United States, 2016 (MMWR Recomm Rep 2016;65[No. RR-1]:1-49) and includes recommendations for managing acute (duration of <1 month), subacute (duration of 1-3 months), and chronic (duration of >3 months) pain. The recommendations do not apply to pain related to sickle cell disease or cancer or to patients receiving palliative o...
Source: MMWR Recomm Rep - November 3, 2022 Category: Epidemiology Authors: Deborah Dowell Kathleen R Ragan Christopher M Jones Grant T Baldwin Roger Chou Source Type: research
CDC Clinical Practice Guideline for Prescribing Opioids for Pain - United States, 2022
MMWR Recomm Rep. 2022 Nov 4;71(3):1-95. doi: 10.15585/mmwr.rr7103a1.ABSTRACTThis guideline provides recommendations for clinicians providing pain care, including those prescribing opioids, for outpatients aged ≥18 years. It updates the CDC Guideline for Prescribing Opioids for Chronic Pain - United States, 2016 (MMWR Recomm Rep 2016;65[No. RR-1]:1-49) and includes recommendations for managing acute (duration of <1 month), subacute (duration of 1-3 months), and chronic (duration of >3 months) pain. The recommendations do not apply to pain related to sickle cell disease or cancer or to patients receiving palliative o...
Source: MMWR Recomm Rep - November 3, 2022 Category: Epidemiology Authors: Deborah Dowell Kathleen R Ragan Christopher M Jones Grant T Baldwin Roger Chou Source Type: research
CDC Clinical Practice Guideline for Prescribing Opioids for Pain - United States, 2022
MMWR Recomm Rep. 2022 Nov 4;71(3):1-95. doi: 10.15585/mmwr.rr7103a1.ABSTRACTThis guideline provides recommendations for clinicians providing pain care, including those prescribing opioids, for outpatients aged ≥18 years. It updates the CDC Guideline for Prescribing Opioids for Chronic Pain - United States, 2016 (MMWR Recomm Rep 2016;65[No. RR-1]:1-49) and includes recommendations for managing acute (duration of <1 month), subacute (duration of 1-3 months), and chronic (duration of >3 months) pain. The recommendations do not apply to pain related to sickle cell disease or cancer or to patients receiving palliative o...
Source: MMWR Recomm Rep - November 3, 2022 Category: Epidemiology Authors: Deborah Dowell Kathleen R Ragan Christopher M Jones Grant T Baldwin Roger Chou Source Type: research
CDC Clinical Practice Guideline for Prescribing Opioids for Pain - United States, 2022
MMWR Recomm Rep. 2022 Nov 4;71(3):1-95. doi: 10.15585/mmwr.rr7103a1.ABSTRACTThis guideline provides recommendations for clinicians providing pain care, including those prescribing opioids, for outpatients aged ≥18 years. It updates the CDC Guideline for Prescribing Opioids for Chronic Pain - United States, 2016 (MMWR Recomm Rep 2016;65[No. RR-1]:1-49) and includes recommendations for managing acute (duration of <1 month), subacute (duration of 1-3 months), and chronic (duration of >3 months) pain. The recommendations do not apply to pain related to sickle cell disease or cancer or to patients receiving palliative o...
Source: MMWR Recomm Rep - November 3, 2022 Category: Epidemiology Authors: Deborah Dowell Kathleen R Ragan Christopher M Jones Grant T Baldwin Roger Chou Source Type: research
CDC Clinical Practice Guideline for Prescribing Opioids for Pain - United States, 2022
MMWR Recomm Rep. 2022 Nov 4;71(3):1-95. doi: 10.15585/mmwr.rr7103a1.ABSTRACTThis guideline provides recommendations for clinicians providing pain care, including those prescribing opioids, for outpatients aged ≥18 years. It updates the CDC Guideline for Prescribing Opioids for Chronic Pain - United States, 2016 (MMWR Recomm Rep 2016;65[No. RR-1]:1-49) and includes recommendations for managing acute (duration of <1 month), subacute (duration of 1-3 months), and chronic (duration of >3 months) pain. The recommendations do not apply to pain related to sickle cell disease or cancer or to patients receiving palliative o...
Source: MMWR Recomm Rep - November 3, 2022 Category: Epidemiology Authors: Deborah Dowell Kathleen R Ragan Christopher M Jones Grant T Baldwin Roger Chou Source Type: research
CDC Clinical Practice Guideline for Prescribing Opioids for Pain - United States, 2022
MMWR Recomm Rep. 2022 Nov 4;71(3):1-95. doi: 10.15585/mmwr.rr7103a1.ABSTRACTThis guideline provides recommendations for clinicians providing pain care, including those prescribing opioids, for outpatients aged ≥18 years. It updates the CDC Guideline for Prescribing Opioids for Chronic Pain - United States, 2016 (MMWR Recomm Rep 2016;65[No. RR-1]:1-49) and includes recommendations for managing acute (duration of <1 month), subacute (duration of 1-3 months), and chronic (duration of >3 months) pain. The recommendations do not apply to pain related to sickle cell disease or cancer or to patients receiving palliative o...
Source: MMWR Recomm Rep - November 3, 2022 Category: Epidemiology Authors: Deborah Dowell Kathleen R Ragan Christopher M Jones Grant T Baldwin Roger Chou Source Type: research
CDC Clinical Practice Guideline for Prescribing Opioids for Pain - United States, 2022
MMWR Recomm Rep. 2022 Nov 4;71(3):1-95. doi: 10.15585/mmwr.rr7103a1.ABSTRACTThis guideline provides recommendations for clinicians providing pain care, including those prescribing opioids, for outpatients aged ≥18 years. It updates the CDC Guideline for Prescribing Opioids for Chronic Pain - United States, 2016 (MMWR Recomm Rep 2016;65[No. RR-1]:1-49) and includes recommendations for managing acute (duration of <1 month), subacute (duration of 1-3 months), and chronic (duration of >3 months) pain. The recommendations do not apply to pain related to sickle cell disease or cancer or to patients receiving palliative o...
Source: MMWR Recomm Rep - November 3, 2022 Category: Epidemiology Authors: Deborah Dowell Kathleen R Ragan Christopher M Jones Grant T Baldwin Roger Chou Source Type: research
CDC Clinical Practice Guideline for Prescribing Opioids for Pain - United States, 2022
MMWR Recomm Rep. 2022 Nov 4;71(3):1-95. doi: 10.15585/mmwr.rr7103a1.ABSTRACTThis guideline provides recommendations for clinicians providing pain care, including those prescribing opioids, for outpatients aged ≥18 years. It updates the CDC Guideline for Prescribing Opioids for Chronic Pain - United States, 2016 (MMWR Recomm Rep 2016;65[No. RR-1]:1-49) and includes recommendations for managing acute (duration of <1 month), subacute (duration of 1-3 months), and chronic (duration of >3 months) pain. The recommendations do not apply to pain related to sickle cell disease or cancer or to patients receiving palliative o...
Source: MMWR Recomm Rep - November 3, 2022 Category: Epidemiology Authors: Deborah Dowell Kathleen R Ragan Christopher M Jones Grant T Baldwin Roger Chou Source Type: research
CDC Clinical Practice Guideline for Prescribing Opioids for Pain - United States, 2022
MMWR Recomm Rep. 2022 Nov 4;71(3):1-95. doi: 10.15585/mmwr.rr7103a1.ABSTRACTThis guideline provides recommendations for clinicians providing pain care, including those prescribing opioids, for outpatients aged ≥18 years. It updates the CDC Guideline for Prescribing Opioids for Chronic Pain - United States, 2016 (MMWR Recomm Rep 2016;65[No. RR-1]:1-49) and includes recommendations for managing acute (duration of <1 month), subacute (duration of 1-3 months), and chronic (duration of >3 months) pain. The recommendations do not apply to pain related to sickle cell disease or cancer or to patients receiving palliative o...
Source: MMWR Recomm Rep - November 3, 2022 Category: Epidemiology Authors: Deborah Dowell Kathleen R Ragan Christopher M Jones Grant T Baldwin Roger Chou Source Type: research
CDC Clinical Practice Guideline for Prescribing Opioids for Pain - United States, 2022
MMWR Recomm Rep. 2022 Nov 4;71(3):1-95. doi: 10.15585/mmwr.rr7103a1.ABSTRACTThis guideline provides recommendations for clinicians providing pain care, including those prescribing opioids, for outpatients aged ≥18 years. It updates the CDC Guideline for Prescribing Opioids for Chronic Pain - United States, 2016 (MMWR Recomm Rep 2016;65[No. RR-1]:1-49) and includes recommendations for managing acute (duration of <1 month), subacute (duration of 1-3 months), and chronic (duration of >3 months) pain. The recommendations do not apply to pain related to sickle cell disease or cancer or to patients receiving palliative o...
Source: MMWR Recomm Rep - November 3, 2022 Category: Epidemiology Authors: Deborah Dowell Kathleen R Ragan Christopher M Jones Grant T Baldwin Roger Chou Source Type: research
Cholera Vaccine: Recommendations of the Advisory Committee on Immunization Practices, 2022
This report describes previously published ACIP recommendations about use of CVD 103-HgR for adults aged 18-64 years and introduces a new recommendation for use in children and adolescents aged 2-17 years. ACIP recommends CVD 103-HgR, the only cholera vaccine licensed for use in the United States, for prevention of cholera among travelers aged 2-64 years to an area with active cholera transmission. Health care providers can use these guidelines to develop the pretravel consultation for persons traveling to areas with active cholera transmission.PMID:36173766 | PMC:PMC9536201 | DOI:10.15585/mmwr.rr7102a1 (Source: MMWR Recomm Rep)
Source: MMWR Recomm Rep - September 29, 2022 Category: Epidemiology Authors: Jennifer P Collins Edward T Ryan Karen K Wong Matthew F Daley Adam J Ratner Grace D Appiah Pablo J Sanchez Bruce J Gutelius Source Type: research
Cholera Vaccine: Recommendations of the Advisory Committee on Immunization Practices, 2022
This report describes previously published ACIP recommendations about use of CVD 103-HgR for adults aged 18-64 years and introduces a new recommendation for use in children and adolescents aged 2-17 years. ACIP recommends CVD 103-HgR, the only cholera vaccine licensed for use in the United States, for prevention of cholera among travelers aged 2-64 years to an area with active cholera transmission. Health care providers can use these guidelines to develop the pretravel consultation for persons traveling to areas with active cholera transmission.PMID:36173766 | PMC:PMC9536201 | DOI:10.15585/mmwr.rr7102a1 (Source: MMWR Recomm Rep)
Source: MMWR Recomm Rep - September 29, 2022 Category: Epidemiology Authors: Jennifer P Collins Edward T Ryan Karen K Wong Matthew F Daley Adam J Ratner Grace D Appiah Pablo J Sanchez Bruce J Gutelius Source Type: research
Cholera Vaccine: Recommendations of the Advisory Committee on Immunization Practices, 2022
This report describes previously published ACIP recommendations about use of CVD 103-HgR for adults aged 18-64 years and introduces a new recommendation for use in children and adolescents aged 2-17 years. ACIP recommends CVD 103-HgR, the only cholera vaccine licensed for use in the United States, for prevention of cholera among travelers aged 2-64 years to an area with active cholera transmission. Health care providers can use these guidelines to develop the pretravel consultation for persons traveling to areas with active cholera transmission.PMID:36173766 | PMC:PMC9536201 | DOI:10.15585/mmwr.rr7102a1 (Source: MMWR Recomm Rep)
Source: MMWR Recomm Rep - September 29, 2022 Category: Epidemiology Authors: Jennifer P Collins Edward T Ryan Karen K Wong Matthew F Daley Adam J Ratner Grace D Appiah Pablo J Sanchez Bruce J Gutelius Source Type: research
Cholera Vaccine: Recommendations of the Advisory Committee on Immunization Practices, 2022
This report describes previously published ACIP recommendations about use of CVD 103-HgR for adults aged 18-64 years and introduces a new recommendation for use in children and adolescents aged 2-17 years. ACIP recommends CVD 103-HgR, the only cholera vaccine licensed for use in the United States, for prevention of cholera among travelers aged 2-64 years to an area with active cholera transmission. Health care providers can use these guidelines to develop the pretravel consultation for persons traveling to areas with active cholera transmission.PMID:36173766 | PMC:PMC9536201 | DOI:10.15585/mmwr.rr7102a1 (Source: MMWR Recomm Rep)
Source: MMWR Recomm Rep - September 29, 2022 Category: Epidemiology Authors: Jennifer P Collins Edward T Ryan Karen K Wong Matthew F Daley Adam J Ratner Grace D Appiah Pablo J Sanchez Bruce J Gutelius Source Type: research
Cholera Vaccine: Recommendations of the Advisory Committee on Immunization Practices, 2022
This report describes previously published ACIP recommendations about use of CVD 103-HgR for adults aged 18-64 years and introduces a new recommendation for use in children and adolescents aged 2-17 years. ACIP recommends CVD 103-HgR, the only cholera vaccine licensed for use in the United States, for prevention of cholera among travelers aged 2-64 years to an area with active cholera transmission. Health care providers can use these guidelines to develop the pretravel consultation for persons traveling to areas with active cholera transmission.PMID:36173766 | PMC:PMC9536201 | DOI:10.15585/mmwr.rr7102a1 (Source: MMWR Recomm Rep)
Source: MMWR Recomm Rep - September 29, 2022 Category: Epidemiology Authors: Jennifer P Collins Edward T Ryan Karen K Wong Matthew F Daley Adam J Ratner Grace D Appiah Pablo J Sanchez Bruce J Gutelius Source Type: research
